Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Psychosom Med. Author manuscript; available in PMC 2012 June 1.
Published in final edited form as:
PMCID: PMC3110520

The folate hydrolase 1561 C>T polymorphism is associated with depressive symptoms in Puerto Rican adults



To examine associations between variants of genes involved in the uptake, retention and metabolism of folate and depressive symptoms, and whether such associations are direct or through mediation by folate or homocysteine.


We performed a cross-sectional analysis of data from 976 Puerto Rican adults, aged 45-75 years, residing in the greater Boston area, Massachusetts. Twelve single nucleotide polymorphisms (SNPs) in genes involved in folate uptake, retention and metabolism were investigated. These include folate hydrolase (FOLH1), folate polyglutamate synthase (FPGS), r-glutamyl hydrolase (GGH), methylene tetrahydrofolate reductase (MTHFR), methionine synthase (MTR), proton-coupled folate transporter (PCFT), and reduced folate carrier (RFC1). The Center for Epidemiologic Studies Depression Scale (CES-D) was used to measure depressive symptoms.


The FOLH1 rs61886492 C>T (or 1561C>T) polymorphism was significantly associated with lower CES-D score (p = .0025), after adjusting for age, sex, population admixture, smoking, and educational attainment. Individuals with the TT and TC genotypes were 49% less likely (odds ratio (OR): 95% confidence interval [CI]: 0.51: 0.29, 0.89) to report mild depressive symptoms (CES-D score ≥16 & ≤26) and 64% less likely (OR: 95% CI: 0.36: 0.18, 0.69) to report moderate to severe depressive symptoms (CES-D score >26), compared to those with the CC genotype. No significant mediation effects by plasma folate or homocysteine on the associations between this SNP and CES-D score were observed.


The FOLH1 1561C>T polymorphism may be associated with risk of depressive symptoms.

Keywords: Depressive symptoms, genetics, polymorphisms, folate, folate hydrolase, glutamate carboxypeptidase II


Folate functions as a coenzyme in single-carbon transfers involving metabolism of amino acids and nucleotide synthesis. Low folate status has been observed in depressed patients (1-3), in severe (1, 2) and prolonged depressive episodes (3) and in those with poor response to antidepressants (2, 3). Supplementation with folic acid has been reported to improve depression on its own (4) and response to antidepressants (5). Total homocysteine, a functional biomarker of folate and vitamin B12 status, has also been linked with depression (6). There is also evidence to suggest that vitamin B12 (7) and vitamin B6 (7, 8) may be associated with depressive symptoms. Nevertheless, not all studies have found significant associations between folate (9-12), vitamin B6 (11), vitamin B12 (10-13) or homocysteine (9, 11-13) and depressive symptoms. Additional studies are needed to clarify the associations between these related vitamins, homocysteine and depression.

Several mechanisms have been suggested for the roles of folate and homocysteine in central nervous system function. Folate may be involved in biopterin-dependent neurotransmitter synthesis (14) and methylation of biogenic amines and phospholipids (15). Folate deficiency increases homocysteine concentration. Homocysteine or its metabolites may have a direct excitotoxic effect on the N-methyl-D-aspartate glutamate receptors (15). In addition, homocysteine can cause dysregulation of promoter-specific DNA methylation, which may directly influence monoaminergic neurotransmission (16).

Genetic association studies may further elucidate the role of folate in depression. The C>T transition at nucleotide 677 in exon 4 of the gene, encoding 5,10-methylenetetrahydrofolate reductase (MTHFR), has been associated with lower plasma folate concentrations and higher risk of depression in some (17, 18), but not all studies (19).

To our knowledge, there are few data on associations of depression with single nucleotide polymorphisms (SNPs) other than the C677T in the MTHFR gene. SNPs in other folate-metabolizing genes, such as those encoding folate hydrolase (FOLH1), proton-coupled folate transporter (PCFT), reduced folate carrier 1 (RFC1), folate receptor 1 (FOLR1), folate polyglutamate synthase (FPGS), r-glutamyl hydrolase (GGH), and methionine synthase (MTR), may also be important (20).

Therefore, we used the Center for Epidemiologic Studies Depression Scale (CES-D) to measure depressive symptoms in a sample of Puerto Rican adults residing in greater Boston area. We aimed to investigate: 1) associations between plasma folate, homocysteine, vitamins B6, B12 and CES-D score; 2) associations of the CES-D score and depressive symptoms with selected SNPs in folate uptake, retention and metabolism related genes (FOLR1, FOLH1, RFC1, PCFT, FPGS, GGH, MTHFR and MTR), and whether observed associations were mediated by folate and homocysteine and moderated by plasma vitamin B6 and B12.


Study population

Data for the current analyses were obtained from the Boston Puerto Rican Health Study, which was initially started in 2004. This is an ongoing study to investigate the influence of social and physical environments and individual risk factors, and their interactions with genes on chronic disorders and diseases among Puerto Rican adults living in Massachusetts. Detailed information about study design and data collection has been described previously (21). Briefly, one Puerto Rican adult, aged 45-75 years, was randomly recruited from each qualified household, identified in the greater Boston area mainly through enumeration of year 2000 Census blocks containing at least 10 Hispanics, within Census tracks containing at least 25 Puerto Rican adults aged 45-75 years. Most (77.4%) of the participants were recruited through this strategy; the remainder were recruited through partnerships with community organizations, random approach at community events, from calls responding to flyers, or from referrals of community members. A home interview was conducted to collect data on demographic variables, acculturation, depressive symptoms, health history, medication use, dietary intake, supplement use and anthropometric measures. Overnight fasting blood samples (12 h) were drawn the day after the home interview or as soon as possible thereafter. Aliquots were saved and stored at −80°C until processed. The Institutional Review Board of the New England Medical Center and Tufts University Health Sciences approved this study; written informed consent was obtained from each participant. A total of 976 participants with available genotype data were included in the current analyses.

The CES-D was used to measure depressive symptoms. This instrument has been shown to have good reliability and discriminating features in Puerto Ricans (22). Data also suggest that the CES-D has relatively high sensitivity and specificity for identification of patients with major depression among middle-aged and older Puerto Ricans (23). Consistent with previous studies, we classified participants as having no depressive symptoms (CES-D score <16), mild depressive symptoms (CES-D score ≥16 & ≤26), or moderate to severe depressive symptoms (CES-D score ≥26) (24). Educational attainment was dichotomized by years in school (≥9 vs. <9 years). Poverty status was defined as total household income was below the threshold released each year by the U.S. Department of Health and Human Services. Acculturation was assessed with seven questions regarding use of English and/or Spanish at work, to watch television, listen to the radio, read newspapers/books, and to talk with neighbors, friends and family members: a summed score ranged from 0 (fully un-acculturated, only using Spanish) to 100 (fully acculturated, only using English) (25). Smoking status was categorized as never (<100 cigarettes in entire life), past and current smoking. Alcohol use was defined as not current, current moderate (≤1 drink daily for women or ≤2 drinks daily for men) or current heavy (>1 drink daily for women and >2 drinks daily for men). Physical activity was measured using a modified Paffenbarger questionnaire of the Harvard Alumni Activity Survey and a score was calculated (21).

Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2). Blood pressure was measured at the beginning, in the middle and at end of the home interview; the latter two were averaged for final analysis. Hypertension was defined as taking antihypertensive medication or systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. Diabetes was defined as taking hypoglycemic medication or a fasting glucose ≥7.0 mmol/L.

Blood metabolites

Plasma folate and vitamin B12 were measured with immunoassay kits (Siemens Medical Solutions, Diagnostics Division, Tarrytown, NY) on the Immulite 1000 analyzer system (Immulite DPC, Los Angeles, CA). Plasma pyridoxal-5′- phosphate (PLP), the active form of vitamin B6, was measured enzymatically using tyrosine decarboxylase (21). Total plasma homocysteine was assayed with Waters HPLC and detected with a Perkin Elmer 650-15 Fluorescence Spectrophotometer (Perkin Elmers., Waltham, MA) (21). Serum creatinine was determined with Olympus Creatinine Reagents on the Olympus AU400e (OSR6178) (Olympus America Inc., Melville, NY).

SNP selection and genotyping

Detailed information about SNP selection and genotyping has been described elsewhere (20). In brief, eight genes involved in folate uptake, retention and metabolism were selected, including FOLR1, FOLH1, RFC1, PCFT, FPGS, GGH, MTHFR and MTR. Selection of SNPs was based on several considerations including: 1) minor allele frequency ≥0.2; 2) no more than one SNP from a specific linkage disequilibrium block; 3) SNPs suggested from previous literature; and 4) the potential for altering transcription process and/or protein activity of the SNP. Final decisions were made based on the capability of a TaqMan probe to successfully detect a SNP. After being isolated from the buffy coat of blood samples, DNA was used for genotyping with custom and predesigned TaqMan SNP assays (Applied Biosystems, Foster City, CA).

Statistical analysis

Plasma folate, PLP, vitamin B12, homocysteine and serum creatine were log-transformed (base 10) to improve normality. The CES-D score was not highly skewed and no improvement of normality was observed when the CES-D score was log-transformed. Therefore, the original continuous CES-D score was used as our primary outcome. Characteristics of participants with mild and with moderate to severe depressive symptoms were compared to those without, using logistic regression for categorical variables as outcomes and general linear models for continuous variables as outcomes. Spearman partial correlation coefficients were calculated between CES-D score and plasma folate, PLP, vitamin B12 and homocysteine and other continuous covariates, adjusting for age and sex. Further, means of the CES-D score were compared across quartiles of plasma folate concentration, adjusting for covariates, with general linear models. First, age, sex, smoking and educational level were adjusted, as suggested in previous studies (17). Secondly, other socioeconomic and life style confounders including poverty, acculturation score, alcohol use and physical activity score were further adjusted. Finally, vascular risk factors including BMI, presence of hypertension and diabetes, and serum creatine (a marker of kidney function) were entered in the final multivariate model. Log-transformed plasma folate was included as an independent variable for the trend test. The same analysis approach was used to compare CES-D score across quartiles of plasma vitamin B12, PLP, and homocysteine, respectively.

Chi-square tests were conducted to examine status of the Hardy-Weinberg equilibrium of genotypes of each SNP. Pairwise linkage disequilibrium (LD) among SNPs was assessed as the squared correlation coefficient (r2) using the genetics package for R (26). General linear regression was used to assess associations between individual SNPs and CES-D score, and multinomial logistic regression was used to assess associations between individual SNPs and mild and moderate to severe depressive symptoms, adjusting for age, sex, smoking, educational level and population admixture, estimated with informative ancestral markers (27). The initial analysis was conducted assuming additive, dominant and recessive genetic models for all SNPs except for FOLH1 rs61886492 (dominant model only). Because Bonferroni correction of multiple testing is overly conservative if tested SNPs are not independent, we used the approach of Li and Ji (28), a modification of method by Nyholt (29), to calculate the effective number of SNPs based on pairwise LD correlation coefficients to correction for multiple testing of additive effects for all SNPs (dominant effect of FOLH1 rs61886492 only) on CES-D score, and on mild and moderate to severe depressive symptoms, respectively. The effective number of SNPs was 11 in the current study. Therefore, the multiple adjusted significant p values should be < .0047, to keep type I error below the level of α = 0.05.

To further examine whether the associations between SNPs and CES-D score were mediated by either folate or homocysteine, a bootstrapping technique suggested by Preacher and Hayes (30) was used for SNPs that remained significant after correction for multiple testing. This bootstrapping mediation model allows us to calculate the direct effect of SNPs on CES-D score, as well as indirect effects through either folate or homocysteine, after adjustment for potential confounding factors.

In addition, we tested whether associations between significant SNPs and CES-D score were moderated by plasma PLP. Plasma PLP was dichotomized to low and high groups at the median. Interaction terms, the product of dichotomized PLP and genotypes, were included in general linear models. We tested the significance of the interaction terms after adjustment for age, sex, population admixture, smoking, and education level. Further adjustments for other risk factors mentioned above were also conducted. We repeated the analysis to test potential interaction between vitamin B12 and genotypes.

A p value of < .0047 for SNP analysis and nominal p < .05 for other analyses were considered statistically significant. Statistical analyses were conducted with SAS version 9.1.3 (SAS Institute Inc, Cary, NC) and R version 2.10.1 (31).


Among the 976 Puerto Rican adults, only 0.1% had folate deficiency (<6.8 nmol/L), 2.8% had plasma vitamin B12 deficiency (<148 pmol/L) and 18.1% of men and 7.4% of women had elevated plasma homocysteine (>13 mmol/L). More than ten percent (10.3%) had vitamin B6 deficiency (PLP <20 nmol/L) and another 16.5 % had insufficient vitamin B6 (PLP ≥20 nmol/L and <30 nmol/L).

Approximately 30% had mild depressive symptoms (CES-D score ≥16 & ≤26), and another 30% had moderate to severe depressive symptoms (Table 1). Those with moderate to severe depressive symptoms were younger, more likely to be women, less educated, less acculturated, less physically active, to have lower income, and to smoke currently, when compared to those without depressive symptoms. Participants with moderate to severe depressive symptoms also had lower concentrations of plasma PLP.

Characteristics of Participants by Depressive Symptoms

Plasma PLP (Spearman partial correlation coefficient r = −.09, p = .006), but not plasma folate (r = −.05, p = .10), vitamin B12 (r = −.05, p = .16) or homocysteine (r = .002, p = .95), was significantly associated with lower CES-D score after adjustment for age and sex. Higher plasma PLP remained significantly associated with lower CES-D score after adjusting for age, sex, smoking and educational levels (p for trend = .003, Table 2). This trend remained marginally significant (p = .08) after further adjustment for poverty status, acculturation score, smoking, alcohol use, physical activity score, diabetes, hypertension, BMI and serum creatine. No significant associations between plasma folate, vitamin B12 and serum creatine and CES-D score were observed (Table 2).

Adjusted Means of CES-D Score by Quartiles of Plasma Folate, Vitamin B12, PLP, and Homocysteine a

SNPs of FOLR1 were not successfully genotyped (20). All other 12 SNPs were in Hardy-Weinberg equilibrium (p > .05 by Chi-square test). FOLH1 rs61886492 C>T was in weak LD with rs202712 C>T (r2 = .04; p < .001) and rs647370 G>A (r2 = .02; p < .001), respectively, whereas rs202712 C>T was in relatively strong LD with rs647370 G>A (r2 = .57; p < .001). GGH rs11545076 T>G was in strong LD with rs3758149 T>C (r2 = .96; p < .001). MTR rs16834521 A>G was in weak LD with rs1805087 A>G (r2 = .12; p < .001), and RFC1 rs2297291 A>G was in relatively strong LD with rs12659 C>T (r2 = .70; p < .001).

The FOLH1 rs61886492 C>T allele (or 1561C>T) was examined with the dominant genetic model because there were only two participants with the TT genotype (Table 3). The FOLH1 rs61886492 C>T allele was associated with lower CES-D score after adjusting for age, sex, smoking, educational level and population admixture (nominal p = .0025). Participants with the T allele were almost 50% less likely to have mild depressive symptoms (nominal p = .02), and 64% less likely to have moderate to severe depressive symptoms (nominal p = .0022), compared to those with the CC genotype. FOLH1 rs202712 C>T (dominant model) and PCFT rs2239907 G>A (recessive model) were also nominally significantly associated with lower CES-D score (nominal p < .05) while MTR rs1805087 A>G was nominally significantly associated with higher CES-D score under either additive or dominant genetic models (both nominal p = .04). However, only the FOLH1 rs61886492 SNP remained statistically significant in relation to lower CES-D score and moderate to severe depressive symptoms after correction for multiple testing.

Genotype Distributions and Their Associations with CES-D Score, Mild, and Moderate to Severe Depressive Symptomsa

We further examined whether the association between the FOLH1 rs61886492 C>T and CES-D score was mediated by folate or homocysteine, using the bootstrapping approach suggested by Preacher and Hayes (30). As shown in figure 1, the total effect of the FOLH1 rs61886492 C>T (coefficient [c] = −4.4, p = .003) on CES-D was similar to the direct effect (coefficient [c′] = − 4.3, p = .004) after control for the pathway mediated by folate, when age, sex, population admixture, smoking and educational level were adjusted. The mediating effect of folate was not significant (95% confidence interval of the bootstrapping coefficient: −0.47 to 0.03). The association between the FOLH1 rs61886492 C>T and CES-D score remained unchanged and was not significantly mediated by folate, even when a series of confounding factors including lifestyle, social economic factors, chronic diseases and plasma PLP and vitamin B12 were considered (Table 4). Similarly, the association between the FOLH1 rs61886492 C>T and CES-D score was not mediated by homocysteine (Figure 1 and Table 4).

Figure 1
The mediating effects of plasma folate (A) and homocysteine (B) on the association between folate hydrolase gene (FOLH1) rs61886492 C>T and Center for Epidemiologic Studies Depression Scale (CES-D) score. Genotypes were coded as 0 = CC and 1 = ...
Mediation of the Effect of FOLH1 rs61886492 C>T on CES-D Score through Plasma Folate and Homocysteinea

We did not observe any significant interaction between the FOLH1 rs61886492 C>T and plasma PLP (in dichotomized form) on CES-D score, when adjusted for age, sex, population admixture, smoking and educational level using general linear models (p >.10) (data not shown). Further adjustment for other covariates including lifestyle, social economic factors, chronic diseases and plasma folate did not change the result (p >.10 for interaction). There was also no interaction between the FOLH1 rs61886492 C>T and vitamin B12 (p > .10 for interaction).


A variant of the FOLH1 gene was significantly associated with CES-D score and with moderate to severe depressive symptoms. However, there were no observed significant associations between CES-D score or depressive symptoms and any of the other SNPs in these genes related to folate uptake, retention and metabolism, after correction for multiple testing.

The frequencies of genotypes of the FOLH1 rs61886492 C>T polymorphism were similar to those observed in most previous studies of other populations (32). In contrast, Halsted et al. did not find a significant association between the FOLH1 rs61886492 C>T polymorphism and depression score in the Hordaland Homocysteine Study in Norway (32). This inconsistency may be due to study design and characteristics of participants. For example, the Hordaland Homocysteine Study did not use the CES-D to estimate depressive symptoms. In addition, only participants aged 70-72 years were included in their analyses (32), whereas we recruited individuals with an age range of 45-75 years old and depressive symptoms was more common with younger age in our study.

Our previous study showed that those with the FOLH1 rs61886492 T alleles (combined CT and TT genotypes) had significantly higher folate concentration than those with the CC genotype in the same sample of participants (20). That may partially explain why the FOLH1 rs61886492 C>T was associated with lower CES-D score. Interestingly, the association of FOLH1 with CES-D score was not mediated by either folate or homocysteine, and was not moderated by either vitamin B6 or vitamin B12 in this population. Alternatively, the hydrolase encoded by FOLH1 possesses N-acetylated α-linked acidic dipeptidase activity, and is therefore also known as glutamate carboxypeptidase II (GCPII) (32). In the brain, FOLH1/GCPII catalyzes the cleavage of N-acetylated-L-aspartyl-L-glutamate to N-acetylated-L-aspartyl and glutamate (32). Recent studies have implicated GCPII as an important regulator of glutamatergic neurotransmission, and have observed dysregulation of brain GCPII expression in psychiatric disorders, including schizophrenia, bipolar states and depression (33). Reduced N-acetylated-L-aspartyl concentrations are thought to indicate neuronal or axonal loss, or dysfunction (34). Inhibiting GCPII is protective in some animal models of neuropsychological disorders, possibly by decreasing glutamate (35). In depression, glutamatergic transmission may be disturbed (36) and antidepressants can change serum glutamate concentrations (37). Together with these observations, our results raise the hypothesis that polymorphisms of FOLH1 could modify the risk of depressive symptoms by modifying GCPII activity. Further studies are needed to verify this hypothesis.

No SNPs of other studied genes were significantly associated with CES-D score or depressive symptoms. One potential reason is that very few participants had folate deficiency in this population because the food supply is now fortified with folic acid, as observed in the NHANES 1999-2000 (38). Although some of the studied SNPs, such as MTHFR C677T, may have functional effects on folate-dependent metabolism and thereby on depression (17, 18), such effects may only be apparent when folate concentrations are limiting. In addition, only a small proportion of our cohort had low plasma vitamin B12 concentrations. This may explain why folate, vitamin B12, as well as homocysteine, were not associated with CES-D score.

On the other hand, plasma PLP, the active form of vitamin B6, was inversely associated with CES-D score after adjustment for age, sex and educational attainment. This is consistent with several previous studies, including one in Hispanic elders (7, 8) but not all (39). In contrast to adequate status of folate and vitamin B12, relatively high prevalence of vitamin B6 deficiency and insufficiency was observed in our study. Biologically, PLP is a key coenzyme in the metabolic pathways of neurotransmitters, including serotonin, dopamine and norepinephrine (40). The role of these monoaminergic neurotransmitters has been well established in the pathophysiology of depression and available antidepressants are based on such mechanisms (41). For example, selective serotonin re-uptake inhibitors and serotonin and norepinephrine re-uptake inhibitors work on serotonin to reduce depressive symptoms (42). The potential beneficial effects of vitamin B6 on depression may be exerted through influencing production of monoaminergic neurotransmitters, and vitamin B6 has been suggested as a therapeutic adjunct to treat conditions with neurotransmitter abnormalities (43).

Nevertheless, antidepressants based on monoaminergic systems require time (generally more than 3 to 4 weeks) to act, and are not effective in approximately 30% of patients with major depressive disorder (41, 44). In the past few years, new mechanisms have emerged, and a disturbed glutamatergic system has been implicated in the pathophysiological process of depression (41). Indeed, drugs targeting the glutamatergic system have shown therapeutic effects on depression (41, 45). Our finding of associations of the FOLH1 (GCPII) gene with mild and moderate to severe depressive symptoms is consistent with the role of the glutamatergic system in depression. More studies on other genes related to the glutamatergic system with depression will be useful to verify this hypothesis.

The prevalence of depressive symptoms (CES-D score ≥16, 60.5%) was higher for the current sample than those observed in previous studies of Puerto Ricans and other Hispanic adults (46). However, a generally high prevalence of depressive symptoms (44.4%) was also >observed in our previous study including Puerto Ricans aged 60 and over in Massachusetts (25). Due to limitations of the CES-D as a screening tool (47), some of those with a high CES-D score may be misclassified and upon closer examination, may not be clinically diagnosed with major depressive disorder. However, a previous study demonstrated that the CES-D scale has high consistency, reliability, and strong discriminating ability between older Puerto Ricans with depression and non-patients, supporting the CES-D as a useful measure in this group (22). To reduce the potential for false positive cases, we classified our participants with a higher cut-off point (>26) to define those with moderate to severe depressive symptoms, and results were stronger for this more severe level of depressive symptoms.

In conclusion, among this middle-aged and older population with high prevalence of mild and moderate to severe depressive symptoms, the FOLH1 rs61886492 (or 1561) C>T, but not SNPs of other studied genes related to folate uptake and metabolism, was associated with CES-D score and presence of depressive symptoms. No mediation effects of folate or homocysteine, or moderation effects of PLP or vitamin B12, were observed. CES-D score was associated with plasma PLP, but not with vitamin B12, folate, or homocysteine. Further investigation of the role of FOLH1 in depressive symptomatology in this and other populations is warranted.


This research was supported by NIH P01 AG023394 and P50 HL105185, JMO HL-54776, DK075030, and US Department of Agriculture Research Service contracts 58-1950-7-707, 58- 1950-9-001 and 53-K06-5-10.


methylene tetrahydrofolate reductase
single nucleotide polymorphism
folate hydrolase
proton-coupled folate transporter
reduced folate carrier
folate receptor 1
folate polyglutamate synthase
r-glutamyl hydrolase
methionine synthase
Center for Epidemiologic Studies Depression Scale
body mass index
linkage disequilibrium
glutamate carboxypeptidase II
standard error
odds ratio
confidence interval


FINANCIAL DISCLOSURES There were no biomedical financial interests or potential conflicts of interest for all authors.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Reynolds EH, Preece JM, Bailey J, Coppen A. Folate deficiency in depressive illness. Br J Psychiatry. 1970;117:287–92. [PubMed]
2. Abou-Saleh MT, Coppen A. The biology of folate in depression: implications for nutritional hypotheses of the psychoses. J Psychiatr Res. 1986;20:91–101. [PubMed]
3. Abou-Saleh MT, Coppen A. Serum and red blood cell folate in depression. Acta Psychiatr Scand. 1989;80:78–82. [PubMed]
4. Guaraldi GP, Fava M, Mazzi F, la Greca P. An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry. 1993;5:101–5. [PubMed]
5. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336:392–5. [PubMed]
6. Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Yoon JS. Predictive value of folate, vitamin B12 and homocysteine levels in late-life depression. Br J Psychiatry. 2008;192:268–74. [PubMed]
7. Skarupski KA, Tangney C, Li H, Ouyang B, Evans DA, Morris MC. Longitudinal association of vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults over time. Am J Clin Nutr. 2010;92:330–5. [PubMed]
8. Merete C, Falcon LM, Tucker KL. Vitamin B6 is associated with depressive symptomatology in Massachusetts elders. J Am Coll Nutr. 2008;27:421–7. [PMC free article] [PubMed]
9. Penninx BW, Guralnik JM, Ferrucci L, Fried LP, Allen RH, Stabler SP. Vitamin B(12) deficiency and depression in physically disabled older women: epidemiologic evidence from the Women’s Health and Aging Study. Am J Psychiatry. 2000;157:715–21. [PubMed]
10. Lindeman RD, Romero LJ, Koehler KM, Liang HC, LaRue A, Baumgartner RN, Garry PJ. Serum vitamin B12, C and folate concentrations in the New Mexico elder health survey: correlations with cognitive and affective functions. J Am Coll Nutr. 2000;19:68–76. [PubMed]
11. Kamphuis MH, Geerlings MI, Grobbee DE, Kromhout D. Dietary intake of B(6-9-12) vitamins, serum homocysteine levels and their association with depressive symptoms: the Zutphen Elderly Study. Eur J Clin Nutr. 2008;62:939–45. [PubMed]
12. Nguyen PH, Grajeda R, Melgar P, Marcinkevage J, DiGirolamo AM, Flores R, Martorell R. Micronutrient supplementation may reduce symptoms of depression in Guatemalan women. Arch Latinoam Nutr. 2009;59:278–86. [PubMed]
13. Beydoun MA, Shroff MR, Beydoun HA, Zonderman AB. Serum folate, vitamin B-12, and homocysteine and their association with depressive symptoms among U.S. adults. Psychosom Med. 2010;72:862–73. [PMC free article] [PubMed]
14. van Praag HM. Depression. Lancet. 1982;2:1259–64. [PubMed]
15. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs. 1994;48:137–52. [PubMed]
16. Hillemacher T, Frieling H, Muschler MA, Bleich S. Homocysteine and epigenetic DNA methylation: a biological model for depression? Am J Psychiatry. 2007;164:1610. [PubMed]
17. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry. 2003;60:618–26. [PubMed]
18. Kelly CB, McDonnell AP, Johnston TG, Mulholland C, Cooper SJ, McMaster D, Evans A, Whitehead AS. The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. J Psychopharmacol. 2004;18:567–71. [PubMed]
19. Gaysina D, Cohen S, Craddock N, Farmer A, Hoda F, Korszun A, Owen MJ, Craig IW, McGuffin P. No association with the 5,10-methylenetetrahydrofolate reductase gene and major depressive disorder: results of the depression case control (DeCC) study and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:699–706. [PubMed]
20. DeVos L, Chanson A, Liu Z, Ciappio ED, Parnell LD, Mason JB, Tucker KL, Crott JW. Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations. Am J Clin Nutr. 2008;88:1149–58. [PMC free article] [PubMed]
21. Tucker KL, Mattei J, Noel SE, Collado BM, Mendez J, Nelson J, Griffith J, Ordovas JM, Falcon LM. The Boston Puerto Rican Health Study, a longitudinal cohort study on health disparities in Puerto Rican adults: challenges and opportunities. BMC Public Health. 2010;10:107. [PMC free article] [PubMed]
22. Mahard RE. The CES-D as a measure of depressive mood in the elderly Puerto Rican population. J Gerontol. 1988;43:P24–P5. [PubMed]
23. Robison J, Gruman C, Gaztambide S, Blank K. Screening for depression in middle-aged and older puerto rican primary care patients. J Gerontol A Biol Sci Med Sci. 2002;57:M308–M14. [PubMed]
24. Schrader G, Cheok F, Hordacre A-L, Guiver N. Predictors of depression three months after cardiac hospitalization. Psychosom Med. 2004;66:514–20. [PubMed]
25. Falcon LM, Tucker KL. Prevalence and correlates of depressive symptoms among Hispanic elders in Massachusetts. J Gerontol B Psychol Sci Soc Sci. 2000;55:S108–16. [PubMed]
26. Gregory Warnes, Gregor Gorjanc, Friedrich Leisch, Michael Man. genetics: Population Genetics. R package version 1.3.4. 2008. with contributions from.
27. Lai CQ, Tucker KL, Choudhry S, Parnell LD, Mattei J, Garcia-Bailo B, Beckman K, Burchard EG, Ordovas JM. Population admixture associated with disease prevalence in the Boston Puerto Rican health study. Hum Genet. 2009;125:199–209. [PMC free article] [PubMed]
28. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005;95:221–7. [PubMed]
29. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74:765–9. [PubMed]
30. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40:879–91. [PubMed]
31. R Development Core Team . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2009.
32. Halsted CH, Wong DH, Peerson JM, Warden CH, Refsum H, Smith AD, Nygard OK, Ueland PM, Vollset SE, Tell GS. Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study. Am J Clin Nutr. 2007;86:514–21. [PubMed]
33. Guilarte TR, Hammoud DA, McGlothan JL, Caffo BS, Foss CA, Kozikowski AP, Pomper MG. Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr Res. 2008;99:324–32. [PMC free article] [PubMed]
34. Benarroch EE. N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology. 2008;70:1353–7. [PubMed]
35. Neale JH, Olszewski RT, Gehl LM, Wroblewska B, Bzdega T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci. 2005;26:477–84. [PubMed]
36. Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M, Invernizzi G. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology. 1998;37:124–9. [PubMed]
37. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand. 1998;97:302–8. [PubMed]
38. Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J, Sampson EJ. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr. 2005;82:442–50. [PubMed]
39. Livingston J, MacLeod P, Applegarth D. Vitamin B6 status in women with postpartum depression. Am J Clin Nutr. 1978;31:886–91. [PubMed]
40. Dakshinamurti K, Paulose CS, Viswanathan M, Siow YL, Sharma SK, Bolster B. Neurobiology of pyridoxine. Ann N Y Acad Sci. 1990;585:128–44. [PubMed]
41. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev. [Review] 2009;61:105–23. [PubMed]
42. Gorman JM, Kent JM. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry. 1999;60(Suppl 4):33–8. discussion 9. [PubMed]
43. Bernstein AL. Vitamin B6 in clinical neurology. Ann N Y Acad Sci. 1990;585:250–60. [PubMed]
44. Alamo C, Lopez-Munoz F. New antidepressant drugs: beyond monoaminergic mechanisms. Curr Pharm Des. 2009;15:1559–62. [PubMed]
45. Machado-Vieira R, Salvadore G, Ibrahim LA, Diaz-Granados N, Zarate CA., Jr. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des. 2009;15:1595–611. [PMC free article] [PubMed]
46. Potter LB, Rogler LH, Moscicki EK. Depression among Puerto Ricans in New York City: the Hispanic Health and Nutrition Examination Survey. Soc Psychiatry Psychiatr Epidemiol. 1995;30:185–93. [PubMed]
47. Santor DA, Coyne JC. Shortening the CES-D to improve its ability to detect cases of depression. Psychol Assess. 1997;9:233–43.